Site is under construction

en Resistance Improvement and Sensitivity Enhancement of Cancer Therapy by a Novel Antitumor Candidate onto A2780 CP and A2780 S Cell Lines زیست شناسی سلولی Cell Biology مقالات اصلی Original Article <div style="text-align: justify;">Background: To overcome cisplatin resistance, the cytotoxicity of a novel antitumor agent on two ovarian cancer cell lines sensitive and resistant to cisplatin was investigated. Methods: MTT assay and flow cytometry were performed to assess the cytotoxicity of a novel water-soluble Pd (II) complex, [Pd(bpy)(pyr-dtc)]NO3 (PBPD), on cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines. Furthermore, variations in the expression of drug resistance gene cluster of differentiation 99 (CD99), signal transducer and activator of transcription 3 (STAT3), octamer-binding transcription factor 4 (OCT4), and multidrug resistance mutation 1 (MDR1) were evaluated using Real-Time PCR. Results: The IC50 values of PBPD in resistant cells were higher than those in sensitive cells. Furthermore, PBPD has a deadlier effect on sensitive cells compared to resistant cells, and the cell survival rate is reduced over time. Flow cytometry revealed that PBPD enhanced the population of living-resistant cells while driving them to apoptosis. PBPD, on the other hand, has a greater effect on the living cell population and has dramatically shifted the population toward apoptosis and necrosis in the sensitive cells. Furthermore, gene expression analysis showed that when sensitive and resistant cells were treated with cisplatin, all resistance genes increased significantly relative to the control. In contrast to OCT4, MDR1, STAT3, and CD99 resistance genes were not significantly elevated in sensitive cells treated with PBPD compared to the control. Thus, the expression of resistance genes in resistant cells treated with PBPD was lower than cisplatin. Conclusions: As a result, PBPD is a promising anticancer agent for CDDP-resistant ovarian cancer.</div> Chemotherapy, Cisplatin, Apoptosis, Drug Resistant, Ovarian Cancers, Organometallic Compound. 374 385 http://rbmb.net/browse.php?a_code=A-10-1311-1&slc_lang=en&sid=1 Sariyeh Mohammadi Hadloo 100319475328460018556 100319475328460018556 No Department of Animal Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran. Homa Mohseni Kouchesfahani kouchesfehani@gmail.com 100319475328460018557 100319475328460018557 Yes Department of Animal Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran. Ali Khanlarkhani 100319475328460018558 100319475328460018558 No Department of Nanotechnology and Advanced Materials, Materials and Energy Research Center, Karaj, Iran. Maryam Saeidifar 100319475328460018559 100319475328460018559 No Department of Nanotechnology and Advanced Materials, Materials and Energy Research Center, Karaj, Iran.